Wenhui Sun1, Chungen Yan2, Shaochang Jia3, Jianhua Hu3. 1. Department of Surgical Oncology, Fuyang People's Hospital Fuyang, China. 2. Department of Gastroenterology, Affiliated Hospital of Shaoxing University Shaoxing 312000, Zhejiang, China. 3. Department of Biotherapy, The 81st Hospital of PLA & Jingdu Hospital Nanjing, China.
Abstract
OBJECTIVE: To investigate the correlation of peripheral DPYD gene polymorphism with 5-fluorouracil (5-FU) susceptibility and side effect in patients with colon cancer. METHODS: The total DNA of peripheral mononuclear cells was extracted in 100 cases of colon cancer patients. Quantitative PCR was conducted to measure DPYD gene 14G1A, A1627G, T85C 3 loci polymorphism, and analyze the correlation of 5-FU susceptibility, side effects with DPYD gene polymorphism. RESULTS: Mutations were detected at position 14G1A (mutation rate 14%), A1627G (mutation rate 11%), and T85C (mutation rate 17%). The effective rate of 3 loci of wild type was significantly higher than that of mutant type (P < 0.05). With respect to side effects such as myelosuppression, hand-foot syndrome, diarrhea, and gastrointestinal reactions, the incidence in mutation type was significantly higher than that in the wild type (P < 0.05). CONCLUSION: DPYD gene polymorphism plays a guiding role in predicting efficacy and toxicity of 5-FU, which can be used as an important reference index of 5-FU individualized administration scheme.
OBJECTIVE: To investigate the correlation of peripheral DPYD gene polymorphism with 5-fluorouracil (5-FU) susceptibility and side effect in patients with colon cancer. METHODS: The total DNA of peripheral mononuclear cells was extracted in 100 cases of colon cancerpatients. Quantitative PCR was conducted to measure DPYD gene 14G1A, A1627G, T85C 3 loci polymorphism, and analyze the correlation of 5-FU susceptibility, side effects with DPYD gene polymorphism. RESULTS: Mutations were detected at position 14G1A (mutation rate 14%), A1627G (mutation rate 11%), and T85C (mutation rate 17%). The effective rate of 3 loci of wild type was significantly higher than that of mutant type (P < 0.05). With respect to side effects such as myelosuppression, hand-foot syndrome, diarrhea, and gastrointestinal reactions, the incidence in mutation type was significantly higher than that in the wild type (P < 0.05). CONCLUSION:DPYD gene polymorphism plays a guiding role in predicting efficacy and toxicity of 5-FU, which can be used as an important reference index of 5-FU individualized administration scheme.
Authors: Kinta M Serve; Jennifer L Darnell; Jody K Takemoto; Neal M Davies; Margaret E Black Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2010-05-19 Impact factor: 3.205
Authors: Chantal W M van Gils; Miriam Koopman; Linda Mol; William K Redekop; Carin A Uyl-de Groot; Cornelis J A Punt Journal: Acta Oncol Date: 2011-11-28 Impact factor: 4.089
Authors: Sabine Weidensee; Peter Goettig; Marko Bertone; Dorothea Haas; Viktor Magdolen; Marion Kiechle; Alfons Meindl; André B P van Kuilenburg; Eva Gross Journal: Clin Biochem Date: 2011-03-21 Impact factor: 3.281
Authors: Andrea Réti; Eva Pap; Vilmos Adleff; András Jeney; Judit Kralovánszky; Barna Budai Journal: Cancer Chemother Pharmacol Date: 2009-10-15 Impact factor: 3.333
Authors: Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio Journal: Cancer Res Date: 2014-03-19 Impact factor: 12.701